3 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow AT-511: new trials by email Literature Review of AT-511 trials Research Report on AT-511
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 AT-527, Placebo - COVID-19 | Phase 2 | Completed | Hoffmann-La Roche | 104 | 2021-02-03 | 2022-10-26 |
| Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting AT-527, Placebo - COVID-19 | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 83 | 2020-05-26 | 2023-03-09 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
Hepatitis C (3) · Hepatitis C, Chronic (3) · COVID-19 (2) · Liver Cirrhosis (1)
Atea Pharmaceuticals, Inc. (4) · Hoffmann-La Roche (1)
Belgium (3) · Moldova (3) · Brazil (2) · Canada (2) · Mauritius (2) · Romania (2) · South Africa (2) · Spain (2) · United States (2) · Argentina (1) · Egypt (1) · Greece (1) · India (1) · Ireland (1) · Latvia (1)
Xiao-Jian Zhou (1) · Xiao-Jian Zhou, PhD (1)
2019 (2)